Persistent pulmonary hypertension in newborn (PPHN) is a syndrome in the newborn period that is estimated to occur in approximately 1.9 per 1,000 live births and significantly increases the risk of mortality and morbidity.
Persistent pulmonary hypertension in newborn (PPHN) is a syndrome in the newborn period that is estimated to occur in approximately 1.9 per 1,000 live births and significantly increases the risk of mortality and morbidity. [1] [2] [3] [4] It is characterized by failure of the rapid fall in pulmonary vascular resistance (PVR) that normally occurs during cardiopulmonary transition at birth. Of the multiple mechanisms that play a critical role in the normal cardiopulmonary transition process, postnatal increase in oxygen tension in the lung is one of the key factors that promote pulmonary vasorelaxation. Supplemental oxygen is therefore the most common therapy used in the management of PPHN. 4 Neonatologists have traditionally used high concentrations of inspired oxygen (FiO 2 ) to treat infants with suspected or confirmed PPHN and aim toward achieving high arterial oxygen tension (PaO 2 ) and oxygen saturation (SpO 2 ). However, recent preclinical evidence suggests that hyperoxia is deleterious and in fact may worsen PVR by inhibiting natural mediators that maintain pulmonary vasorelaxation. 5, 6 While multiple large randomized controlled trials have been performed in preterm
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Abstract
Objective To evaluate practice variations amongst neonatologists regarding oxygen management in neonates with persistent pulmonary hypertension of newborn (PPHN). Study Design An online survey was administered to neonatologists to assess goal oxygenation targets and oxygen titration practices in PPHN. Response variations were assessed and intergroup comparisons performed. Results Thirty-three percent (492) of neonatologists completed the survey. Twentyeight percent reported using specific oxygen titration guidelines. Majority of respondents used a combination of oxygen saturation (SpO 2 ) and arterial oxygen tension (PaO 2 ) initially to titrate oxygen. Seventy percent of the respondents used higher goal SpO 2 > 95% or 95 to 98% and thirty-eight percent of the respondents used PaO 2 > 80 mm Hg. Physicians with extracorporeal membrane oxygenation experience and those with greater than ten years neonatal intensive care unit experience inclined toward use of SpO 2 alone for oxygen titration and aimed for lower range of SpO 2 and PaO 2 targets. Greater proportion of neonatologists who employed specific oxygen titration guidelines used lower SpO 2 targets. Conclusion Wide practice variations exist amongst neonatologists regarding optimal SpO 2 and PaO 2 targets and oxygen titration practices in the management of PPHN.
infants to identify optimal SpO 2 targets, there is paucity of evidence in near-term and term infants with PPHN to guide optimal oxygenation targets that will maximize pulmonary vasodilatation without significantly inducing deleterious effects of hyperoxia. The responses to individual questions were summarized by counts and percentages and used to determine practice variability. Comparisons were made between neonatologists with and without ECMO experience, with less than or greater than ten years of NICU experience, and between those who used guidelines for titration of FiO 2 and those who didn't. Chi square test or Fisher exact test was used for analysis and level of significance was set at p < 0.05.
Results
The survey was sent to 1,500 neonatologists and a total of 492 neonatologists completed the survey. The response rate was 33% (492/1,500).
Demographics
A total of 36% (176/492) of all respondents managed neonates on ECMO. In all, 69% (340/492) of the respondents had more than ten years of experience as a neonatologist and of those 74% (252/340) had greater than twenty years of experience. 
Target Oxygen Saturation and Arterial Oxygen Tension Ranges
We next evaluated practice variations in the target ranges of preductal SpO 2 and PaO 2 used to titrate FiO 2 in infants with PPHN. A total of 70% of all respondents chose to target higher ranges of SpO 2 of greater than 95% or 95 to 98%, whereas, 30% of all respondents used lower SpO 2 target ranges of 92 to 96% or 92 to 98%. In all, 39% (189/492) of all respondents aimed for goal preductal SpO 2 greater than 95% and did not use an upper limit to target SpO 2 (►Fig. 2A) . As for PaO 2 , 37% (184/492) of all respondents aimed to achieve target PaO 2 of 60 to 100 mm Hg and 38% (187/492) of respondents choose to maintain PaO 2 greater than 80 mm Hg. While 25% (121/492) of physicians did not use PaO 2 for oxygen titration after initial stabilization, 11% (52/492) of respondents chose to target PaO 2 greater than 120 mm Hg (►Fig. 3A). In summary, wide variations were noted amongst neonatologists with respect to the target ranges of SpO 2 and PaO 2 used for management of PPHN.
When compared based on ECMO experience, 22% (38/176) of neonatologists with ECMO experience used PaO 2 80 to 120 mm Hg compared with 31% (97/316) neonatologists without ECMO experience (p ¼ 0.03; (►Fig. 3B). ECMO experienced physicians aimed for lower SpO 2 target of 92 to 96% or 92 to 98% compared with non-ECMO experienced physicians 
Subsequent Weaning of Oxygen
Since sudden hypoxemic episodes worsen PVR, slow wean of FiO 2 to avoid hyperoxia-hypoxemia fluctuations, is one of key components of PPHN management. We therefore sought to examine the rate at which neonatologists would wean FiO 2 if 
Oxygen Titration Guidelines
Lastly, we questioned whether specific nurse and/or respiratory therapist driven protocol or clinical practice guideline was used 
Discussion
The present study demonstrates that wide practice variations exist amongst neonatologists with respect to the use of supplemental oxygen in PPHN management. There is a lack of consensus of the appropriate parameters, SpO 2 versus PaO 2 and their target ranges, to guide titration of FiO 2 . The survey also reveals that majority of NICUs do not use specific guidelines or protocols for FiO 2 titration to standardize treatment. These variations in practice reflect a lack of evidence to support one strategy over other. PPHN is a syndrome in the newborn period that contributes substantially to neonatal mortality and morbidity.
2,3,11,12
While the underlying etiology and degree of hypoxemia are the most important determinants of the incidence and severity of long-term morbidities, some of the therapies used for PPHN treatment and variations in practice amongst centers may also be a contributing factor. Previous studies reported significant practice variations with respect to best perceived techniques to improve oxygenation, timing of initiation of inhaled nitric oxide, use of surfactant, and type of vasopressor used. 13, 14 In this study, we specifically examined practice variations in the use of supplemental oxygen which is the most common therapy used for treatment of PPHN and oxidative stress is known to contribute to long-term morbidities. Both hypoxemia and hyperoxia worsen PVR and an optimal range of SpO 2 and PaO 2 exists to maintain the least PVR while avoiding hyperoxia-induced lung injury as shown in a lamb model of PPHN and in a small group of infants with bronchopulmonary dysplasia and pulmonary hypertension, who underwent cardiac catheterization. 6, 15 Whether similar results will be observed in neonates with acute PPHN is unknown. As a reflection of lack of adequate evidence in this topic, significant variations in practice were noted in our survey where two-thirds of respondents preferred to use higher SpO 2 targets of greater than 95% or 95 to 98% and remaining one-third used lower SpO 2 targets of 92 to 96% or 92to 98%. More than one-third of respondents did not use an upper limit of SpO 2 target. Majority of respondents also used PaO 2 to titrate FiO 2, and amongst them almost half chose to target PaO 2 greater than 80 mm Hg. This indicates that majority of neonatologists were vigilant toward avoiding hypoxemia but were tolerant to hyperoxia. It is interesting to note that a small proportion of neonatologists (6%) preferred to use 100% oxygen for a prolonged period of time regardless of the infant's actual oxygenation status until they were confident that the pulmonary vascular reactivity stabilized clinically. The strategy to use 100% oxygen which was commonly used in the past, has become less popular in the recent years due to emerging evidence that high FiO 2 exposure induces substantial oxidative stress, alters responses to endogenous and exogenous pulmonary vasodilators, and alters mechanisms that induce vasoconstriction or prevent vasorelaxation.
6,16-18
Using a simple online survey, we were able to specifically evaluate the FiO 2 weaning practices in the setting of acute PPHN. Two-thirds of the physicians selected a cautious strategy of weaning FiO 2 by 2% every 30 minutes or 1 hour if infant's SpO 2 was greater than the target range. The reasons for the same were not collected as part of the survey and we speculate that it may be due to a theoretical concern for rebound increase in PVR with lower levels or rapid fluctuation in oxygenation status. Such a slow rate of wean of oxygen may result in excess proportion of time spent above goal parameters and exposure to detrimental effects of hyperoxia. There is no published data validating appropriate oxygen weaning strategies and further research is needed to test the detrimental effects of hyperoxia or risk of rebound pulmonary vasoconstriction with different weaning strategies.
Physicians working in units with specific oxygen titration guidelines or protocols aimed for lower SpO 2 and PaO 2 targets when compared with units without specific guidelines. Importantly, only about a quarter of them used standard guidelines for oxygen titration. Use of evidence-based clinical practice guidelines has been shown to reduce practice variations and improve outcomes.
19-22 Use of standard protocols for oxygen titration in infants with PPHN may decrease hypoxemia-hyperoxia fluctuations and cumulative oxygen exposure. Appropriate use of oxygen targets may also potentially reduce exposure to other supportive PPHN therapies and thereby potentially improve outcomes while reducing overall cost. We focused on neonatologist members of the Section of Perinatal Pediatrics of American Academy of Pediatrics and we believe the results can be generalized. The survey cohort is a mixed representation of inborn and out born centers as well as academic and nonacademic centers throughout the United States with variable level of experience in neonatology and ECMO. A response rate of 33% is as good as one can usually get from an internet-based survey, however, it may not be the best representative sample. Response bias has been reported to be less of a concern for physician surveys compared with general population surveys.
23
Our study has some limitations. The responses reflect the responders' perception and it does not always translate into what is actually performed at the bedside. Second, we used certain specific ranges of SpO 2 and PaO 2 targets and FiO 2 weaning frequency in the survey that are most commonly used in clinical practice, and did not include open-ended choices. The response choices are therefore overlapping and the respondents may have felt limited by the choices offered. Nevertheless, this study provides important information about the significant variation in oxygen titration practices for PPHN management in the neonate.
Conclusion
Supplemental oxygen is one of the mainstays of PPHN treatment which is associated with high mortality and morbidity. Using a simple and pragmatic survey, we demonstrated that significant variations in practice exist with respect to optimal target ranges of SpO 2 and PaO 2 and optimal strategies to titrate FiO 2 to achieve target SpO 2 and PaO 2. Further preclinical and clinical studies are needed to inform evidence-based guidelines. The results of this survey provide useful avenues to stimulate research that can guide appropriate management of oxygen for treatment of PPHN in neonates.
